760 results on '"Borén, Jan"'
Search Results
2. Contribution of intestinal triglyceride-rich lipoproteins to residual atherosclerotic cardiovascular disease risk in individuals with type 2 diabetes on statin therapy
3. Synthesis, spectroscopic characterization, DFT and molecular docking of N-(3-cyano-4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl) naphthalene-1-sulfonamide derivatives
4. Extracellular vesicles transport RNA between cells: Unraveling their dual role in diagnostics and therapeutics
5. Design and synthesis of novel JNK inhibitors targeting liver pyruvate kinase for the treatment of non-alcoholic fatty liver disease and hepatocellular carcinoma
6. Adipocyte PI3K links adipostasis with baseline insulin secretion at fasting through an adipoincretin effect
7. Sulfone-based human liver pyruvate kinase inhibitors – Design, synthesis and in vitro bioactivity
8. Non-coronary peripheral arterial complications in people with type 2 diabetes: a Swedish retrospective cohort study
9. Non-coronary arterial outcomes in people with type 1 diabetes mellitus: a Swedish retrospective cohort study
10. Cardiac arrhythmias and conduction abnormalities in patients with type 2 diabetes
11. Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial
12. Lipoprotein(a) Is Markedly More Atherogenic Than LDL: An Apolipoprotein B-Based Genetic Analysis
13. High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner
14. The acute effect of different NAD+ precursors included in the combined metabolic activators
15. Longitudinal metabolomics analysis reveals the acute effect of cysteine and NAC included in the combined metabolic activators
16. AdipoR2 recruits protein interactors to promote fatty acid elongation and membrane fluidity
17. Cerebrospinal fluid sulfatide isoforms lack diagnostic utility in separating progressive from relapsing-remitting multiple sclerosis
18. Tuning liver pyruvate kinase activity up or down with a new class of allosteric modulators
19. Metabolism of triglyceride-rich lipoproteins in health and dyslipidaemia
20. Cardiomyocytes, sphingolipids and cardio myotoxicity
21. Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning
22. Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study
23. Anthraquinone derivatives as ADP-competitive inhibitors of liver pyruvate kinase
24. The role of circulating galectin-1 in type 2 diabetes and chronic kidney disease: evidence from cross-sectional, longitudinal and Mendelian randomisation analyses
25. Modified lipid metabolism and cytosolic phospholipase A2 activation in mesangial cells under pro-inflammatory conditions
26. Sphingosine 1-phosphate mediates adiponectin receptor signaling essential for lipid homeostasis and embryogenesis
27. Biosynthesis and Metabolism of ApoB-Containing Lipoproteins.
28. Aging AdipoR2‐deficient mice are hyperactive with enlarged brains excessively rich in saturated fatty acids.
29. A network-based approach reveals the dysregulated transcriptional regulation in non-alcoholic fatty liver disease
30. Intussusceptive Angiogenesis in Human Metastatic Malignant Melanoma
31. Cholesterol efflux promoting function of high-density lipoproteins in calcific aortic valve stenosis
32. Stratification of patients with clear cell renal cell carcinoma to facilitate drug repositioning
33. APRIL limits atherosclerosis by binding to heparan sulfate proteoglycans
34. Combined Metabolic Activators with Different NAD+ Precursors Improve Metabolic Functions in the Animal Models of Neurodegenerative Diseases.
35. Current Status of COVID-19 Therapies and Drug Repositioning Applications
36. A systems biology approach for studying neurodegenerative diseases
37. Classification of clear cell renal cell carcinoma based on PKM alternative splicing
38. Quantifying atherogenic lipoproteins for lipid-lowering strategies: Consensus-based recommendations from EAS and EFLM
39. Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement
40. Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects
41. Metabolic network-based stratification of hepatocellular carcinoma reveals three distinct tumor subtypes
42. Palmitic acid causes increased dihydroceramide levels when desaturase expression is directly silenced or indirectly lowered by silencing AdipoR2
43. Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE-/- mice
44. Cardiac expression of the microsomal triglyceride transport protein protects the heart function during ischemia
45. Cyclic AMP-binding protein Epac1 acts as a metabolic sensor to promote cardiomyocyte lipotoxicity
46. Retraction notice to “Combined metabolic activators improve metabolic functions in the animal models of neurodegenerative diseases” [Life Sci. 314 (2023) 121325]
47. Corrigendum to “Discovery of therapeutic agents targeting PKLR for NAFLD using drug repositioning” [eBioMedicine, 2022;83:104214]
48. Pyruvate kinase L/R is a regulator of lipid metabolism and mitochondrial function
49. Localised lipid accumulation detected in infarcted mouse heart tissue using ToF-SIMS
50. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.